Cargando…
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies across many chronic inflammatory diseases, but recently this promise has been overshadowed by questions regarding associated cardiovascular and cancer risk emerging from the ORAL Surveillance phase 3b/4 post-marketing...
Autores principales: | Yang, Victor, Kragstrup, Tue W., McMaster, Christopher, Reid, Pankti, Singh, Namrata, Haysen, Stine R., Robinson, Philip C., Liew, David F. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632271/ https://www.ncbi.nlm.nih.gov/pubmed/37490213 http://dx.doi.org/10.1007/s40264-023-01333-0 |
Ejemplares similares
-
Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022) -
Management of Influenza Virus Infections with Neuraminidase Inhibitors: Detection, Incidence, and Implications of Drug Resistance
por: McKimm-Breschkin, Jennifer L.
Publicado: (2012) -
Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
por: Nishio, Makoto, et al.
Publicado: (2022) -
Diagnosing and Managing Postherpetic Neuralgia
por: Nalamachu, Srinivas, et al.
Publicado: (2012) -
Syphilis in Dermatology: Recognition and Management
por: Whiting, Cleo, et al.
Publicado: (2023)